Advanced
Synthesis and Anti Bacterial and Anti-ulcer Evaluation of New S-mannich Bases of 4,6-diaryl-3,4-dihydropyrimidin-2(1H)-thiones
Synthesis and Anti Bacterial and Anti-ulcer Evaluation of New S-mannich Bases of 4,6-diaryl-3,4-dihydropyrimidin-2(1H)-thiones
Journal of the Korean Chemical Society. 2013. Apr, 57(2): 234-240
Copyright © 2013, Korea Chemical Society
  • Received : December 26, 2012
  • Accepted : March 05, 2013
  • Published : April 20, 2013
Download
PDF
e-PUB
PubReader
PPT
Export by style
Article
Author
Metrics
Cited by
TagCloud
About the Authors
Venkateshwarlu Kodhati
University College of Pharmaceutical Sciences, Kakatiya University, Warangal – 506009, India
Malla Reddy Vanga
Narsimha Reddy Yellu
University College of Pharmaceutical Sciences, Kakatiya University, Warangal – 506009, India

Abstract
The synthesis of title compounds were accomplished by synthetic sequence shown in Scheme 1 . Chalcones on cyclocondensation with thiourea in ethanol and potassium hydroxide under reflux yielded the respective dihydropyramidin- 2(1 H )-thiones. Each of the dihydropyrimidin thiones was, then subjected to the Mannich condensation in alkaline medium using three different secondary amines, viz., dimethylamine, diethylamine and morpholine to obtain a new series of S-Mannich bases. All the synthesised compounds (C1−C15) were evaluated for their antiulcer and antibacterial activities. Compounds C4, C5, C6, C14 and C15 exhibited relatively more potent antiulcer activity but not comparable to the standard; Omeprazole, while C1, C2, C3 and C13 were moderate in activity at 100 mg/kg p.o. All the compounds (C1−C15) showed mild to moderate activity against both Gram-positive ( S.aureus, L.delbrueckii ) and Gram-negative ( P.vulgaris, E.coli ) bacteria. Amongst the compounds tested, only C6, C9, C12 and C15 were found to be potent.
Keywords
INTRODUCTION
Pyrimidines are of considerable chemical and biological significance. Many pyrimidine derivatives have displayed diverse pharmacological activities such as anti-inflammatory, 1 3 antimicrobial, 4 analgesic, 5 antiplatelet, 6 antithrombotic, 6 antineoplastic, 7 antianginal, 8 antiulcer 9 activities, etc., keeping in view the importance of these dihydropyrimidines in the field of medicine and biology and in continuation of our work on new dihydropyrimidine derivatives, an attempt has now been made to synthesize novel SMannich bases and to investigate their antiulcer and antibacterial activities.
The present work describes the synthesis of S-Mannich bases of dihydropyrimidin-2(1 H )-thiones and evalution of antiulcer activity using aspirin-induced model and antibacterial activity against Gram-(+ve) ( S.aureus, L.delbrueckii ) and Gram-(–ve) ( P.vulgaris, E.coli ) bacteria. A new series of S-Mannich bases of dihydropyrimidin-2(1 H )- thiones ( C1−C15 ) were synthesized by the Mannich reaction on five different 3,4-dihyropyrimidine 2(1 H )-thiones ( B1−B5 ) using aqueous formaldehyde, potassium carbonate and three different secondary amines, viz., dimetylamine, diethylamine and morpholine. All the compounds prepared were characterized by their physical and spectral (IR, NMR, Mass) data. Results of biological activities showed that some of these new S-Mannich bases possess antiulcer and antibacterial activities, with a variation in potencies.
RESULTS AND DISCUSSION
- Chemistry
A novel series of [4,6-substituted diaryl-3,4-dihyropyramidine- 2-yl-thiomethyl]-amines were synthesized on the lines of a synthetic route presented in 1 . The desired compounds were synthesized as follows: initially, an equimolar quantities of differently substituted acetophenones and substituted benzaldehydes in the presence of sodium hydroxide, through a mixed aldol condensation yielded the corresponding chalcones ( A1−A5 ). Each of these chalcones ( A1−A 5 ) was heated under reflux with thiourea in the presence of sodium hydroxide to yield the respective 4,6-diaryl dihydropyrimidine-2(1 H )-thione ( B1− B5 ). The Mannich condensation of thiones, B1−B5 with three secondary amines (dimethylamine, diethylamine and morpholine) and formaldehyde, in dimethyl sulfoxide (DMSO) afforded the corresponding Mannich bases ( C1−C15 ). These compounds have been characterized by their IR, 1 HNMR and Mass spectral data and elemental analyses. The physical data of the chalcones and dihydropyrimidin- 2(1 H )-thiones are presented in 1 and that of their S-Mannich bases in 2 , respectively.
PPT Slide
Lager Image
Substituents: R1 = p-Cl, p-OH, m-NO2; R2 = p-Cl, p-OCH3, p-N(CH3)2; R3 = dimethylamino, diethylamino & 4- morpholino. Reaction conditions: a = aq. NaOH, ethanol; b = thiourea, KOH, ethanol; c = secondary amines (dimethylamine, diethylamine or morpholine), aq.formaldehyde (37%), K2CO3 and DMSO.
- Spectral Analyses
A sharp singlet peak at δ 3.40 ppm indicates the presence of CH proton (C 5 of pyrimidine), a characteristic signal at δ 3.62 ppm as a singlet is assigned to CH2 proton (S- CH2−N ), a multiplet at δ 7.2−7.8 ppm indicates the presence of aromatic protons (Ar−H) The mass spectra of all the synthesized compounds ( C1−C15 ) showed molecular ion peak at M+1 and M+2, characteristic of the presence of sulphur.
Physical data of chalcones and dihydropyrimidin-2(1H)-thiones
PPT Slide
Lager Image
*n-hexane–ethyl acetate (1:1) on silica gel.
BIOLOGICAL EVALUATION
- Antiulcer Activity13−16
Antiulcer activity of all the synthesized compounds was evaluated by using aspirin induced ulcer model in Albino rats. Albino rats weighing 150−200 g were divided into different groups consisting of six animals per group and starved for 24 hrs. The test compounds were administered orally 30 min prior to aspirin administration (100 mg/kg). Control group received only vehicle (1% sodium carboxy methyl cellulose), whereas the standard group received omeprazole 20 mg/kg. After 5 hr of drug treatment all the animals were sacrificed according to the CPCSEA guidelines and stomach was cut open in the greater curvature, washed with ice cold saline and cleaned. The gastric mucosa was examined for ulcer scoring by using 4× binocular magnifier .The ulcer score is according to its severity in comparison with that of the standard. Ulcer scores were recorded as follows:
The severity of the mucosal damage was assessed by Ulcer Index (UI) and it was calculated by using the formula:
The mean ulcer index and percentage protection produced by different test compounds are presented in 3 along with their statistical significance.
Physical data of S-Mannich bases of dihydropyrimidin-2(1H)-thiones
PPT Slide
Lager Image
*n-hexane−ethyl acetate (1:2) on silica gel.
Results of antiulcer activity of different compounds
PPT Slide
Lager Image
*Ulcer index expressed in Mean±S.D. Test dose for control, standard and test compounds: 100 mg/kg. n=6, values expressed as Mean ± SD, statistical comparison was performed using One-Way ANOVA followed by Dunnett’s post-test, *p≤ 0.05, **p≤0.01, ***p≤0.001, ns − non significant, compared to control.
In vivo antiulcer activity of the synthesized compounds (C1−C15) was evaluated by aspirin-induced ulcer model using Omeprazole as the standard drug. Ulcer index and percentage protection of test compounds was calculated. From the results, it could be inferred that the compunds C4 , C5 , C6 , C14 and C15 possess more antiulcer activity while compounds C1 , C2 , C3 , C9 and C13 were moderate in their activity when compared with the control group. The compounds C7 , C8 , C10 , C11 and C12 were lacking significant activity. However, the antiulcer activity of the present series of compounds is not at all comparable with that of the standard Omeprazole.
Antibacterial activity of synthesised compounds (C1−C15) and their MIC (㎍/ml)
PPT Slide
Lager Image
Antibacterial activity of synthesised compounds (C1−C15) and their MIC (㎍/ml)
- Antibacterial Activity17
The antibacterial activity of the test compounds was assayed, against four different strains of bacteria, i.e., Staphylococcus aureus and Lactobacillus delbrueckii (Gram positive) Proteus vulgaris and Escherichia coli (Gram negative) by the agar diffusion method. Generally, the antibacterial activity of a compound is expressed in terms of its ability to inhibit the growth of bacteria in nutrient broth or agar. Ciproflaxacin was used as the standard drug. The compounds and their minimum inhibitory concentrations (MIC) in ㎍/ml are presented in 4 .
In vitro antibacterial activity of all the synthesized compounds ( C1−C15 ) showed to be mild to moderate against both the Gram-positive ( S.aureus, L.delbrueckii ) and Gramnegative ( P.vulgaris, E.coli ) bacteria. Amongst them, the compounds C6 , C9 , C12 and C15 were found to be relatively more potent.
EXPERIMENTAL SECTION
All the chemicals were of synthetic grade and commercially procured from Sigma Aldrich, Mumbai, India. Melting points were determined by open capillary method and were uncorrected. IR spectra were recorded on FTIR (Bruker Alpha-E) by KBr disc method. The 1 H NMR spectra were recorded at 400MHz in DMSO-d 6 as solvent and TMS as an internal standard using BRUKER ADVANCE 400 instrument. Mass spectra were recorded on PEP-SCIUX-APIQ pulsar mass spectrophotometer. Elemental analyses were performed on Perkin-Elmer EAL240 elemental analyzer.
- General Procedure for Synthesis of Chalcones (A)
A mixture of 22gm of sodium hydroxide in 200 ml of water and 100gm of rectified spirit in a 500 ml bolt head flask was provided with a mechanical stirrer. The flask was immersed in a bath of crushed ice; 52 gm (0.43 mol) of freshly distilled acetophenone was added while stirring and then followed by 46gm (44 ml, 0.43 mol) of pure benzaldehyde. The temperature of the reaction mixture was maintained at about 25 °C (limits are: 15−30 °C) and stirred vigorously until the reaction mass was so thick that stirring was no longer possible (2−3 hr). Stirrer was removed and the reaction mixture was kept in an ice chest or refrigerator, overnight. The product was filtered and washed with cold water until the washings were neutral to litmus followed with 20 ml of ice cold, rectified spirit and dried. It was purified by recrystallization from ethanol to give a pure compound. 10
- General Procedure for Synthesis of 4,6-diaryl-pyrimidin- 2-thiol (B)
A mixture of 0.01 moles of chalcone, 0.01 moles of thiourea and potassium hydroxide (1gm) in 20 ml ethanol was heated under reflux for 6 hr. The reaction was monitored by TLC. After completion of the reaction, the contents were cooled to room temperature and poured into ice cold water (50 ml) while stirring. The solid thus resulted was filtered, washed with portions of cold water and dried. It was purified by recrystallization from ethanol to give a pure compound. 11
- General Procedure for the Synthesis of S-Mannich Bases of 4,6-diaryl-dihydropyrimidin-2(1H) Thione (C)
Dihydropyrimidine thione (0.005 moles) was dissolved in dimethyl sulfoxide (25 ml) in a conical flask and stirred with 37% formaldehyde (0.01 moles) then added anhydrous potassium carbonate (1.0gm), appropriate secondary amine (0.005 mol) and continued the stirring magnetically for about 2 hrs. The reaction mixture was then heated under reflux for about 5 hrs. Completion of reaction was confirmed by TLC and then kept in refrigerator for 48 hr, filtered the product, washed with small portions of cold water and dried. The crude product was purified by recrystallization from petroleum ether-chloroform (1:1) mixture. 12
- Characterization Data of Synthesised S-Mannich Bases (C1−C15)
1-((4,6-bis(4-chlorophenyl)pyrimidin-2-yl)thio)-N,Ndimethylmethanamine (C1):
IR (KBr, cm −1 ): 3050 (=C−H str, aromatic), 1648 (C=N str, pyrimidine), 1602 and 1425 (C=C str, aromatic), 770 (C−Cl str), 620 (C−S−C str); 1H NMR (400Hz, DMSO-d 6 ) δ ppm: 2.26(s, 6H, 2CH3), 4.00 (s, 2H, CH2), 7.21 (s, 1H, CH), 7.28−8.00 (m, 8H, Ar−H); EI-MS : 389; Ana. Calcd. for C 19 H 17 Cl 2 N 3 S: C, 58.06; H, 4.39; N, 10.77. Found: C, 58.03; H, 4.35; N, 10.71%.
N-(((4,6-bis(4-chlorophenyl)pyrimidin-yl)thio)methyl)- N-ethylethanamine (C2):
IR (KBr, cm −1 ): 3048 (=C-H str, aromatic), 1648(C=N str, pyrimidine) 1605 and 1428 (C=C str, aromatic), 750 (C−Cl str), 618 (C−S−C str); 1H NMR (400 Hz, DMSO-d 6 ) δ ppm: 1.04 (t, 6H, 2CH 3 ), 2.65 (q, 4H, 2CH 2 ), 3.99 (s, 2H, CH 2 ), 7.20 (s, 1H, CH) 7.26−8.01 (m, 8H, Ar−H); EI-MS : 417; Ana. Calcd. for C 21 H 21 Cl 2 N 3 S: C, 60.29; H, 5.06; N, 10.04. Found: C, 60.27; H, 5.02; N, 10.01%.
4-(((4,6-bis(4-chlorophenyl)pyrimidin-2-yl)thio)methyl)morpholine (C3):
IR (KBr, cm −1 ): 3052 (=C−H str, aromatic), 1645 (C=N str, pyrimidine) 1601 and 1426 (C=C str, aromatic), 755 (C−Cl str), 619 (C−S−C str); 1H NMR (400 Hz, DMSO-d 6 ) δ ppm: 2.98 (t, 4H, 2CH 2 ), 3.68 (t, 4H, 2CH 2 ) 3.97 (s, 2H, CH 2 ), 7.20 (s, 1H, CH), 7.27−8.00 (m, 8H, Ar−H); EI-MS : 431; Ana. Calcd. for C 21 H 19 Cl 2 N 3 OS: C, 58.34; H, 4.43; N, 9.72. Found C, 58.36; H, 4.41; N, 9.69%.
1-((4-(4-chlorophenyl)-6-(4-methoxyphenyl)pyrimidin- 2-yl)thio)-N,N-dimthyimethanamine (C4):
IR (KBr, cm −1 ): 3049 (=C−H str, aromatic), 1650 (C=N str, pyrimidine) 1602 and 1429 (C=C str, aromatic), 758 (C−Cl str), 622 (C−S−C str); 1H NMR (400 Hz, DMSO-d 6 ) δ ppm: 2.28 (s, 6H, 2CH 3 ), 3.85 (s, 3H, CH 2 ), 4.00 (s, 2H, CH 2 ), 7.22 (s, 1H, CH), 7.28−8.02 (m, 8H, Ar−H); EI-MS : 385; Ana. Calcd. for C 20 H 20 ClN 3 OS: C, 62.25; H, 5.22; N, 10.89. Found C, 62.21; H, 5.19; N, 10.85%.
N-(((4-(4-chlorophenyl)-6-(4-methoxyphenyl)pyrimidin- 2-yl)thio)methyl)-N-ethylethanamine (C5):
IR (KBr, cm−1) 3052 (=C−H str, aromatic), 1645 (C=N str, pyrimidine) 1605 and 1430 (C=C str, aromatic), 760 (C−Cl str), 625(C−S−C str); 1H NMR (400 Hz, DMSO-d 6 ) δ ppm: 1.02 (t, 6H, 2CH 3 ), 2.64 (q, 4H, 2CH 2 ), 3.83 (s, 3H, OCH 3 ), 3.99 (s, 2H, CH 2 ), 7.25 (s, 1H, CH), 7.29−8.00 (m, 8H, Ar-H); EI-MS : 413; Ana. Calcd. for C 24 H 22 ClN 3 OS: C, 63.83; H, 5.84; N, 10.15. Found C, 63.81; H, 5.80; N, 10.11%.
4-(((4-(4-chlorophenyl)-6-(4-methoxyphenyl)pyrimidin- 2-yl)thio)methyl)morphine (C6):
IR (KBr, cm −1 ): 3054 (=C−H str, aromatic), 1651 (C=N str, pyrimidine) 1600 and 1429 (C=C str, aromatic), 761 (C−Cl str), 621(C−S−C str); 1H NMR (400 Hz, DMSO-d 6 ) δ ppm: 2.96 (t, 4H, 2CH 2 ), 3.70 (t, 4H2CH 2 ), 3.84 (s, 3H, OCH 3 ), 4.02 (s, 2H, CH 2 ), 7.23 (s, 1H, CH), 7.28−8.02 (m, 8H, Ar−H); EI-MS : 427; Ana.Calcd.for C 22 H 22 ClN 3 O 2 S: C, 61.74; H, 5.18; N, 9.82. Found C, 61.71; H, 5.12; N, 9.79%.
4-(6-(4-chlorophenyl)-2-(((dimethylamino)methyl)thio)pyrimidin- 4-yl)-N,N-dimethylaniline (C7):
IR (KBr, cm −1 ): 3049 (=C−H str, aromatic), 1649 (C=N str, pyrimidine) 1604 and 1427 (C=C str, aromatic), 754 (C−Cl str), 617 (C−S−C str); 1H NMR (400 Hz, DMSO-d 6 ) δ ppm: 2.28 (s, 6H, 2CH 3 ), 3.06 (s, 6H, Ar−N(CH 3 ) 2 ), 3.99 (s, 2H, CH 2 ), 7.22 (s, 1H, CH), 7.26−8.00 (m, 8H, Ar−H); EI-MS : 398; Ana. Calcd. for C 21 H 23 ClN 4 S: C, 63.22; H, 5.81; N, 14.04. Found C, 63.19; H, 5.79; N, 14.01%.
4-(6-(4-chlorophenyl)-2-(((diethylamino)methyl)thio)pyrimidin- 4-yl)-N,N-dimethylaniline (C8):
IR (KBr, cm −1 ): 3047 (=C−H str, aromatic), 1647 (C=N str, pyrimidine) 1605 and 1428 (C=C str, aromatic), 757 (C−Cl str), 621 (C−S−C str); 1H NMR (400 Hz, DMSO-d 6 ) δ ppm: 1.03 (t, 6H, 2CH 3 ), 2.64 (q, 4H, 2CH 2 ), 3.04 (s, 6H, Ar−N(CH 3 ) 2 ), 4.02 (s, 2H, CH 2 ), 7.20 (s, 1H, CH), 7.26−8.00 (m, 8H, Ar−H); EI-MS : 426; Ana. Calcd. for C 23 H 27 ClN 4 S: C, 64.69; H, 6.37; N, 13.12. Found C, 64.65; H, 6.32; N, 13.11%.
4-(6-(4-chlorophenyl)-2-((morpholinomethyl)thio)pyrimidin- 4-yl)-N,N-dimethylaniline (C9):
IR (KBr, cm −1 ): 3055 (=C−H str, aromatic), 1645 (C=N str, pyrimidine) 1601 and 1430 (C=C str, aromatic), 761 (C−Cl str), 619 (C−S−C str); 1H NMR (400 Hz, DMSO-d 6 ) δ ppm: 2.96 (t, 4H, 2CH 2 ), 3.06 (s, 6H, Ar−N (CH 3 ) 2 ), 3.66 (t, 4H, 2CH 2 ), 4.01 (s, 2H, CH 2 ), 7.21 (s, 1H, CH), 7.25−8.00 (m, 8H, Ar−H); EI-MS : 440; Ana. Calcd. for C 23 H 25 ClN 4 OS: C, 62.64; H, 5.71; N, 12.70. Found C, 62.61; H, 5.69; N, 12.68%.
4-(6-(4-chlorophenyl)-2-(((dimethylamino)methyl)thio)pyrimidin- 4-yl)phenol (C10):
IR (KBr, cm −1 ): 3320 (O−H str), 3055 (=C−H str, aromatic), 1645 (C=N str, pyrimidine) 1601 and 1430 (C=C str, aromatic), 755 (C−Cl str), 619 (C−S−C str); 1H NMR (400 Hz, DMSO-d 6 ) δ ppm: 2.27 (s, 6H, 2CH 3 ), 3.98 (s, 2H, CH 2 ), 5.35 (s, 1H, Ar−OH), 7.23 (s, 1H, CH), 7.27−8.02 (m, 8H, Ar−H); EI-MS : 371; Ana. Calcd. for C 19 H 18 ClN 3 OS: C, 61.36; H, 4.88; N, 11.30. Found C, 61.32; H, 4.82; N, 11.29%.
4-(6-(4-chlorophenyl)-2-(((diethylamino)methyl)thio)pyrimidin- 4-yl)phenol (C11):
IR (KBr, cm −1 ): 3325 (O−H str), 3055 (=C−H str, aromatic), 1645 (C=N str, pyrimidine) 1601 and 1430 (C=C str, aromatic), 765 (C−Cl str), 619 (C−S−C str); 1H NMR (400 Hz, DMSO-d 6 ) δ ppm: 1.02 (t, 6H, 2CH 3 ), 2.66 (q, 4H, 2CH 2 ), 3.99 (s, 2H, CH 2 ), 5.33 (s, 1H, Ar−OH), 7.20 (s, 1H, CH), 7.26−8.01 (m, 8H, Ar−H); EI-MS : 399; Ana. Calcd. for C 21 H 22 ClN 3 OS: C, 63.36; H, 5.54; N, 10.51. Found C, 63.32; H, 5.52; N, 10.49%.
4-(6-(4-chlorophenyl)-2-(morpholinomethyl)thio)pyrimidin- 4-yl)phenol (C12):
IR (KBr, cm −1 ): 3329 (O−H str), 3055 (=C−H str, aromatic), 1645 (C=N str, pyrimidine) 1601 and 1430 (C=C str, aromatic), 769 (C−Cl str), 619 (C−S−C str); 1H NMR (400 Hz, DMSO-d 6 ) δ ppm: 2.96 (t, 4H, 2CH 2 ), 3.69 (t, 4H, 2CH 2 ), 3.97 (s, 2H, CH 2 ), 5.31 (s, 1H, Ar−OH), 7.21 (s, 1H, CH), 7.27−8.01 (m, 8H, Ar−H); EI-MS : 413; Ana. Calcd. for C 21 H 20 ClN 3 O 2 S: C, 60.94; H, 4.87; N, 10.15. Found C, 60.91; H, 4.85; N, 10.12%.
1-((4-(4-chlorophenyl)-6-(3-nitrophenyl)pyrimidin-2- yl)thio)-N,N-dimethylmethanamine (C13):
IR (KBr, cm −1 ): 3061 (=C−H str, aromatic), 1650 (C=N str, pyrimidine) 1606 and 1428 (C=C str, aromatic), 1525 and 1350 (N=O str, aromatic), 760 (C−Cl str), 619 (C−S− C str); 1H NMR (400 Hz, DMSO-d 6 ) δ ppm: 2.26 (s, 6H, 2CH 3 ), 4.00 (s, 2H, CH 2 ), 7.25 (s, 1H, CH), 7.29−8.0 5(m, 8H, Ar−H); EI-MS : 400; Ana. Calcd. for C 19 H 17 ClN 4 O 2 S: C, 56.93; H, 4.27; N, 13.98. Found C, 56.92; H, 4.25; N, 13.95%.
N-(((4-(4-chlorophenyl)-6-(3-nitrophenyl)pyrimidin- 2-yl)thio)methyl)-N-ethylethanamine (C14):
IR (KBr, cm −1 ): 3052 (=C−H str, aromatic), 1647 (C=N str, pyrimidine) 1601 and 1429 (C=C str, aromatic), 1528 and 1352 (N=O str, aromatic), 751 (C−Cl str), 618 (C−S− C str); 1H NMR (400 Hz, DMSO-d 6 ) δ ppm: 1.05 (s, 6H, 2CH 3 ), 2.64 (q, 4H, 2CH 2 ), 3.99 (s, 2H, CH 2 ), 7.23 (s, 1H, CH), 7.26−8.01 (m, 8H, Ar−H); EI-MS: 428; Ana. Calcd. for C 21 H 21 ClN 4 O 2 S: C, 58.80; H, 4.93; N, 13.06. Found C, 58.79; H, 4.91; N, 13.02%.
N-(((4-(4-chlorophenyl)-6-(3-nitrophenyl)pyrimidin- 2-yl)thio)methyl)morpholine (C15):
IR (KBr, cm −1 ): 3058 (=C−H str, aromatic), 1645 (C=N str, pyrimidine) 1606 and 1429 (C=C str, aromatic), 1530 and 1354 (N=O str, aromatic), 762 (C−Cl str), 616 (C−S− C str); 1H NMR (400 Hz, DMSO-d 6 ) δ ppm: 2.95 (t, 4H, 2CH 2 ), 3.67 (t, 4H, 2CH 2 ), 4.01 (s, 2H, CH 2 ), 7.23 (s, 1H, CH), 7.28−8.05 (m, 8H, Ar−H); EI-MS : 442; Ana. Calcd. for C 21 H 19 ClN 4 O 3 S: C, 56.95; H, 4.32; N, 12.65. Found C, 56.93; H, 4.31; N, 12.63%.
CONCLUSION
The S-Mannich bases of 4,6-diaryl-3,4-dihydropyrimidin- 2(1 H )-thiones were synthesised by a facile method. All the synthesised compounds ( C1−C15 ) were evaluated for their anti-ulcer and antibacterial activities. Compounds C4 , C5 , C6 , C14 and C15 exhibited more potent anti-ulcer activity; compounds C6 , C9 , C12 and C15 have more potent antibacterial activity.
Acknowledgements
The authors are thankful to UCPSc, Kakatiya University for facilities. One of the authors (K.Venkateshwarlu) is grateful to the management of Vaagdevi College of Pharmacy for their help and encouragement. And the publication cost of this paper was supported by the Korean Chemical Society.
References
Sushil kumar B. S. , Devanand S. B. 2003 Acta Pharm 53 223 -
Sham M. , Sondhi N. S. , Monika J. , Ashok Kumar B. 2005 Med. Chem. 13 6158 -    DOI : 10.1016/j.bmc.2005.06.063
Dravyakar B. R. , Kawade D. P. , Bhusari K. P. 2007 Ind. J. Heterocycl. Chem. 16 301 -
Nagaraj A. , Sanjeev Reddy C. 2008 Iran. Chem. Soc. 5 262 -    DOI : 10.1007/BF03246116
Rathod I. S. , Baheta K. G. 2005 Indian J. Pharm. Sci. 67 593 -
Brun O. , Ballabeni V. , Barocellin E. 2004 Biorg. Med. Chem. 12 553 -
Sinythises J. R. 1979 Psychoneuroendocrinology 4 177 -    DOI : 10.1016/0306-4530(79)90001-5
Lavilla R. J. 2002 Chem. Soc. 1 1141 -
Patil P. A. , Bhole R. P. , Chikhale R. V. , Bhusari K. P. 2009 Inter. J. Chem Tech Res. 1 373 -
Vogle A. I. , Tachell A. R. , Furnis B. S. , Hannaford A. J. , Smith P. W. G. 1996 Vogel’s Book of Practical Organic Chemistry 5th ed Prentice Hall
Amit R. T. , Dipti K. D , Naresh R. R. , Viresh H. S. 2008 ARKIVOC 11 131 -
Shah T. B. , Gupte A. , Patel M. R. , Chaudhari V. S. , Patel H. , Patel V. C. 2009 Ind. J. Chem. 48B 88 -
Barrett W. E. , Rutledge R. , Plummer A. J. , Yonkman F. F. 1953 J. Pharmacol. Exp. Ther. 108 305 -
Hemmati M. , Razvani A. , Diahanguini B. 1973 Pharmacology 9 374 -    DOI : 10.1159/000136411
Shay H. , Komarow S. A. , Fels S. S. , Meranze D. , Gruenstein M. , Siplet H. 1973 Gastroenterol 5 43 -
Gerhard Vogel H. 2002 Drug Discovery and Evaluation 2nd ed. Springers
Fung T. J. C. , Minassian B. 2000 Antimicrob Agents Chemother 44 3351 -    DOI : 10.1128/AAC.44.12.3351-3356.2000